【摘要】：醫(yī)藥制造業(yè)是國民經(jīng)濟中一個具有特殊地位的產(chǎn)業(yè),關系到國民之健康、社會之穩(wěn)定以及經(jīng)濟之發(fā)展,是世界公認的知識、技術、資本密集的高技術產(chǎn)業(yè)。我國醫(yī)藥制造業(yè)起步相對較晚但發(fā)展迅速,年均增速一直保持在兩位數(shù)以上,在制造業(yè)各大類行業(yè)中始終位居前列。2016年2月14日,李克強總理在國務院常務會議上提出醫(yī)藥產(chǎn)業(yè)關系民眾健康,市場需求巨大,應積極扶持中醫(yī)藥發(fā)展,全面推動醫(yī)藥產(chǎn)業(yè)創(chuàng)新升級。這說明,作為醫(yī)藥產(chǎn)業(yè)核心的醫(yī)藥制造業(yè)已被推到了我國創(chuàng)新改革的風口浪尖。吉林省地處我國東北部地區(qū),醫(yī)藥制造業(yè)獨具特色,中成藥生產(chǎn)企業(yè)規(guī)模占比近70%。本文通過數(shù)據(jù)的對比與研究發(fā)現(xiàn),雖然吉林省醫(yī)藥制造業(yè)已具備一定規(guī)模,但知識化、技術化水平較低,發(fā)展模式仍屬于資源依賴性。本文通過借鑒國內(nèi)外學者關于創(chuàng)新及創(chuàng)新效率理論與方法的最新研究成果,對吉林省醫(yī)藥制造業(yè)創(chuàng)新效率進行測算,測算結(jié)果表明:吉林省醫(yī)藥制造業(yè)近幾年創(chuàng)新效率相比全國其他地區(qū)有上升趨勢,排名相對靠前,但主要是由于創(chuàng)新投入尚處在規(guī)模報酬遞增階段,是創(chuàng)新投入增加對創(chuàng)新效率拉動的結(jié)果;雖然純技術效率也有所提升,但跟醫(yī)藥制造業(yè)發(fā)達地區(qū)(如山東省、江蘇省等)相比仍然相距甚遠。更近一步,本文選擇具有代表性的山東省和四川省進行案例分析,并對吉林省醫(yī)藥制造業(yè)各影響因素進行實證檢驗,最終得出結(jié)論:倡導制藥企業(yè)創(chuàng)新文化,增加制藥企業(yè)創(chuàng)新投入強度,是提升吉林省醫(yī)藥制造業(yè)創(chuàng)新效率的根本動力;只有充分激發(fā)制藥企業(yè)的創(chuàng)造活力,才能夠引領吉林省醫(yī)藥制造業(yè)早日走上創(chuàng)新升級之路。在此基礎上,本文結(jié)合吉林省醫(yī)藥制造業(yè)發(fā)展特征,有針對性地提出對策和建議。
[Abstract]:Pharmaceutical manufacturing industry is an industry with special status in the national economy, which is related to the health of the people, the stability of society and the development of economy. It is recognized as a high-tech industry with knowledge, technology and capital density in the world. China's pharmaceutical manufacturing industry started relatively late but developed rapidly, with an average annual growth rate of more than double digits, and has always been in the forefront of all kinds of manufacturing industries. On February 14, 2016, Premier Li Keqiang put forward at the executive meeting of the State Council that the pharmaceutical industry has a healthy relationship with the people, and the market demand is enormous, so we should actively support the development of traditional Chinese medicine and promote the innovation and upgrading of the pharmaceutical industry in an all-round way. This shows that the pharmaceutical manufacturing industry as the core of the pharmaceutical industry has been pushed to the forefront of innovation and reform in China. Jilin Province is located in the northeast of China, the pharmaceutical manufacturing industry has its own characteristics, the scale of the Chinese patent medicine production enterprises accounts for nearly 70%. Through the comparison and study of the data, it is found that although the pharmaceutical manufacturing industry in Jilin Province has a certain scale, but the level of knowledge and technology is low, the development mode is still resource-dependent. Based on the latest research results of innovation and innovation efficiency theories and methods at home and abroad, this paper measures the innovation efficiency of pharmaceutical manufacturing industry in Jilin Province. The results show that the innovation efficiency of the pharmaceutical manufacturing industry in Jilin Province has an upward trend compared with other regions in the country in recent years, and the ranking is relatively high, but mainly because the innovation investment is still in the stage of increasing returns on a scale. It is the result of the increase of innovation input to the efficiency of innovation. Although pure technology efficiency has also improved, it is still far from the pharmaceutical manufacturing developed regions (such as Shandong, Jiangsu Province, etc.). Further, this paper chooses Shandong Province and Sichuan Province, which are representative, to carry on the case analysis, and carries on the empirical examination to the Jilin Province medicine manufacturing industry each influence factor, finally draws the conclusion: advocates the pharmaceutical enterprise innovation culture, Increasing the innovation input intensity of pharmaceutical enterprises is the fundamental motive force to improve the innovation efficiency of pharmaceutical manufacturing industry in Jilin Province. Only by fully stimulating the creative vitality of pharmaceutical enterprises can we lead the pharmaceutical manufacturing industry in Jilin Province to embark on the road of innovation and upgrading as soon as possible. On this basis, this paper puts forward countermeasures and suggestions according to the development characteristics of pharmaceutical manufacturing industry in Jilin Province.
【學位授予單位】：吉林大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：F426.72;F273.1

【參考文獻】

相關期刊論文 前10條

1 苗婧;楊海亮;;京津冀協(xié)同發(fā)展與河北產(chǎn)業(yè)創(chuàng)新升級研究[J];經(jīng)濟研究參考;2016年53期

2 徐偉;仲憶雯;郝梅;;基于因子分析和熵權法的我國醫(yī)藥產(chǎn)業(yè)創(chuàng)新政策實施效果評價[J];上海醫(yī)藥;2016年15期

3 羅文華;孫利華;周靜;;中國醫(yī)藥產(chǎn)業(yè)結(jié)構高級化評價[J];中國新藥雜志;2016年14期

4 李潔;周秋芳;;江蘇醫(yī)藥產(chǎn)業(yè)集群知識溢出效應實證分析[J];南京中醫(yī)藥大學學報(社會科學版);2016年02期

5 苗葳;;實施創(chuàng)新驅(qū)動戰(zhàn)略 推動通化醫(yī)藥健康產(chǎn)業(yè)發(fā)展[J];延邊黨校學報;2016年02期

6 趙冠宇;;關于我國醫(yī)藥產(chǎn)業(yè)集群投資風險的分析[J];時代金融;2016年05期

7 王紅倩;張崢;;基于SD的醫(yī)藥產(chǎn)業(yè)技術創(chuàng)新系統(tǒng)研究[J];上海理工大學學報;2016年01期

8 武興連;席曉宇;姚文兵;;基于齒輪模型的醫(yī)藥產(chǎn)業(yè)與區(qū)域經(jīng)濟耦合協(xié)調(diào)度研究[J];中國新藥雜志;2016年02期

9 嚴朕;修國義;;黑龍江省醫(yī)藥產(chǎn)業(yè)集群創(chuàng)新能力評價研究[J];科技與管理;2016年01期

10 蔡仲曦;干榮富;;從醫(yī)藥產(chǎn)業(yè)鏈維度尋找醫(yī)藥工業(yè)發(fā)展之契機[J];中國醫(yī)藥工業(yè)雜志;2016年01期

，

本文編號：2367847